叶美辰,卢天舒,魏峰,崔雷,张斯扬,项荣武
YE M eichen,LU Tianshu,WEI Feng,CUI Lei,ZHANG Siyang,XIANG Rongwu

• 1:沈阳药科大学医疗器械学院
• 2:北部战区总医院医学信息数据室
• 3:中国医科大学医学信息学院

摘要(Abstract)：

目的 分析程序性细胞死亡蛋白-1抑制剂(programmed cell death receptor 1,PD-1)药物不良反应的研究热点，了解该领域发展现状并为未来研究提供方向和参考。方法 以PubMed数据库中收录的关于PD-1抑制剂的药物不良反应文献为来源，以“antineoplastic agents, immunological/adverse effects”[Mesh] and “programmed cell death 1 receptor/antagonists and inhibitors”[Mesh]为检索策略，以2010-2020年为限定时间。采用书目共现分析系统软件抽取主要主题词/副主题词，获得高频主题词论文矩阵，利用gCLUTO软件对其进行聚类分析。结果 检索得到411篇文献，20个高频主题词，可视化分析后得到联合治疗、非小细胞肺癌、黑色素瘤和疗法比较4个聚类。结论 皮炎是程序性细胞死亡蛋白-1抑制剂较常见的不良反应，非小细胞肺癌患和晚期黑色素瘤为在抗PD-1治疗上最常被研究的肿瘤类型，Nivolumab是最常被研究的PD-1抑制剂类药物，对相关科学研究有一定帮助。
Objective In order to analyze the research hotspots of adverse reactions of programmed cell death protein-1 inhibitors, understand the development status of this field and provide direction and reference for future research.Methods This paper takes the literatures about adverse reactions of programmed cell death protein-1 inhibitors in PubMed database as the source literature, and uses bibliographic co-occurrence analysis software to count the main subject headings in the literature.The frequency of subject words and high-frequency words were intercepted to obtain the high-frequency subject words thesis matrix.The clustering software was used to cluster them to analyze the research hotspots of adverse reactions of programmed cell death protein-1 inhibitors.Results 411 related articles were detected, 20 high-frequency keywords were obtained, and finally 4 research hotspots were obtained.Conclusion The analysis of the 4 research hotspots will lay a foundation for grasping the research status and development trend of adverse reactions of programmed cell death protein-1 inhibitors, and will be helpful to the relevant scientific research of professionals.

关键词(KeyWords)： 程序性细胞死亡蛋白-1抑制剂;免疫检查点抑制剂;不良反应;研究热点;聚类分析
programmed cell death protein-1 inhibitors;immune checkpoint inhibitors;adverse reactions;research hotspots;cluster analysis

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金资助项目(U1908215);; “辽宁省兴辽英才计划”资助项目(XLYC2005014)

作者(Author): 叶美辰,卢天舒,魏峰,崔雷,张斯扬,项荣武
YE M eichen,LU Tianshu,WEI Feng,CUI Lei,ZHANG Siyang,XIANG Rongwu

DOI: 10.14066/j.cnki.cn21-1349/r.2021.0300

参考文献(References)：

• [1] PARDOLL D M.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
• [2] LIU Y H,CUI L.Research hotspots in current foreign and domestic medical decision support system[J].Chinese Journal of Medical Library and Information Science (中华医学图书情报杂志),2016,25(11):49-55.
• [3] CUI L,LIU W,YAN L,et al.Development of a text mining system based on the co-occurrence of bibliographic items in literature databases[J].New Technology of Library and Information Service(现代图书情报技术),2008,168(8):70-75.
• [4] RASMUSSEN M,KARYPIS G.gCLUTO:An interactive clustering,visualization,and analysis system [EB/OL].[2016-07-28].http://glaros.dtc.umn.edu/gkhome/node/174.
• [5] ZHOU W J,HE M J,LIAN H,et al.Clinical analysis of immune-related adverse events of PD-1 immune checkpoint inhibitors[J].J Intervent Radiol(介入放射学杂志),2021,30(1):29-33.
• [6] WARNER A B,POSTOW M A.Combination controversies:checkpoint inhibition alone or in combination for the treatment of melanoma?[J].Oncology (Williston Park),2018,32(5):228-234.
• [7] JANJIGIAN Y Y,MARON S B,CHATILA W K,et al.First-line pembrolizumab and trastuzumab in HER2-positive oesophageal,gastric,or gastro-oesophageal junction cancer:an open-label,single-arm,phase 2 trial[J].Lancet Oncol,2020,21(6):821-831.
• [8] TOI Y,SUGAWARA S,SUGISAKA J,et al.Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer[J].JAMA Oncol,2019,5(3):376-383..
• [9] HAMMER M,BAGLEY S,AGGARWAL C,et al.Thoracic imaging of non-small cell lung cancer treated with anti-programmed death receptor-1 therap[J].Curr Probl Diagn Radiol,2019,48(2):142-147.
• [10] NARDIN C,JEAND′HEUR A,BOUILLER K,et al.Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients[J].J Am Acad Dermatol,2020,82(3):770-772.
• [11] NAQASH A R,FILE D M,ZIEMER C M,et al.Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa.A single-institutional case-series[J].J Immunother Cancer,2019,7(1):4.
• [12] AMINI-ADLE M,BALME B,DALLE S.Grover′s-like drug eruption under anti-PD-1 therapy for metastatic melanoma[J].Ann Dermatol Venereol,2018,145(12):802-803.
• [13] MIN LEE C K,LI S,TRAN D C,et al.Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes:a retrospective case-control study[J].J Am Acad Dermatol,2018,79(6):1047-1052.
• [14] OPDIVO(nivolumab)injection[EB/OL].(2015-03-04)[2021-10-03].http://www.Accessdata.fda.gov/drugsatfda_docs/label/2015/125527s000lbl.pdf.
• [15] Approval letter[EB/OL].(2014-12-22)[2021-10-08].http://www.accessdata.fda.gov/drugsatfda_docs/appletter/ 2014/125554Orig1s000ltr.pdf.
• [16] Approval letter[EB/OL].(2015-03-04)[2021-10-16].http://www.accessdata.fda.gov/drugsatfda_docs/appletter/ 2015/125527Orig1s000ltr.pdf.
• [17] LEACH D R,KRUMMEL M F,ALLISON J P.Enhancement of antitumor immunity by CTLA-4 blockade[J].Science,1996,271(5256):1734-1736.
• [18] CHEMNITZ J M,PARRY R V,NICHOLS K E,et al.SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation,but only receptor ligation prevents T cell activation[J].J Immunol,2004,173(2):945-954.
• [19] KHOJA L,DAY D,WEI-WU CHEN T,et al.Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors:a systematic review[J].Ann Oncol,2017,28(10):2377-2385.
• [20] KOMAKI Y,KOMAKI F,YAMADA A,et al.Meta-analysis of the risk of immune-related adverse events with anticytotoxic t-lymphocyte-associated antigen 4 and antiprogrammed death 1 therapies[J].Clin Pharmacol Ther,2018,103(2):318-331.
• [21] WEINMANN SC,PISETSKY DS.Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors[J].Rheumatology(Oxford),2019,58(Suppl 7):vii59-vii67.
• [22] DAS R,BAR N,FERREIRA M,et al.Early B cell changes predict autoimmunity following combination immune checkpoint blockade[J].J Clin Invest,2018,128(2):715-720.
• [23] NAIDOO J,PAGE D B,LI B T,et al.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J].Ann Oncol,2015,26(12):2375-2391.
• [24] CHU C,SUN Y,PAN Y.Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic?[J].Oral Oncol,2020,107(8):104860.
• [25] GHOSH N,TIRPACK A,CHAN K K,et al.Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy:results of a registry survey[J].J Immunother Cancer,2020,8(2):e001550.